{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:46:15Z","timestamp":1794008775584,"version":"4.8.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001349","name":"MOH | National Medical Research Council","doi-asserted-by":"publisher","award":["MOH-CTGIIT17may-0001"],"award-info":[{"award-number":["MOH-CTGIIT17may-0001"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-62203-0","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:57:33Z","timestamp":1753876653000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Effects of sacubitril\/valsartan on hypertensive heart disease: the REVERSE-LVH randomized phase 2 trial"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0447-9956","authenticated-orcid":false,"given":"Vivian","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7091-7880","authenticated-orcid":false,"given":"Mayank","family":"Dalakoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qishi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desiree-Faye","family":"Toh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6498-2846","authenticated-orcid":false,"given":"Redha","family":"Boubertakh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Bryant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tar-Choon","family":"Aw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Hang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2023-8177","authenticated-orcid":false,"given":"A. Mark","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Di\u0301ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8079-4618","authenticated-orcid":false,"given":"Roger","family":"Foo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6628-194X","authenticated-orcid":false,"given":"Stuart A.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1903-0018","authenticated-orcid":false,"given":"Carolyn SP","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0221-6094","authenticated-orcid":false,"given":"Thu-Thao","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9867-4390","authenticated-orcid":false,"given":"Calvin WL","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"62203_CR1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jama.2016.19043","volume":"317","author":"MH Forouzanfar","year":"2017","unstructured":"Forouzanfar, M. H. et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 19902015. JAMA. 317, 165\u2013182 (2017).","journal-title":"JAMA"},{"key":"62203_CR2","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.jacc.2023.04.007","volume":"81","author":"R Mohebi","year":"2023","unstructured":"Mohebi, R. et al. Effect of 2022 ACC\/AHA\/HFSA criteria on stages of heart failure in a pooled community cohort. J. Am. Coll. Cardiol. 81, 2231\u20132242 (2023).","journal-title":"J. Am. Coll. Cardiol."},{"key":"62203_CR3","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jchf.2017.04.012","volume":"5","author":"FH Messerli","year":"2017","unstructured":"Messerli, F. H., Rimoldi, S. F. & Bangalore, S. The transition from hypertension to heart failure: contemporary update. JACC Heart Fail. 5, 543\u2013551 (2017).","journal-title":"JACC Heart Fail."},{"key":"62203_CR4","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1161\/HYPERTENSIONAHA.123.21708","volume":"81","author":"A Gonz\u00e1lez","year":"2024","unstructured":"Gonz\u00e1lez, A. et al. Myocardial Interstitial fibrosis in hypertensive heart disease: from mechanisms to clinical management. Hypertens 81, 218\u2013228 (2024).","journal-title":"Hypertens"},{"key":"62203_CR5","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/j.jacc.2018.02.021","volume":"71","author":"A Gonz\u00e1lez","year":"2018","unstructured":"Gonz\u00e1lez, A., Schelbert, E. B., D\u00edez, J. & Butler, J. Myocardial interstitial fibrosis in heart failure. J. Am. Coll. Cardiol. 71, 1696\u20131706 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"62203_CR6","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","volume":"375","author":"LM Ruilope","year":"2010","unstructured":"Ruilope, L. M. et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 375, 1255\u20131266 (2010).","journal-title":"Lancet"},{"key":"62203_CR7","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJV McMurray","year":"2014","unstructured":"McMurray, J. J. V. et al. Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 371, 993\u20131004 (2014).","journal-title":"N. Engl. J. Med."},{"key":"62203_CR8","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/ejhf.474","volume":"18","author":"Y Suematsu","year":"2016","unstructured":"Suematsu, Y. et al. LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice. Eur. J. Heart Fail. 18, 386\u2013393 (2016).","journal-title":"Eur. J. Heart Fail."},{"key":"62203_CR9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.118.005565","volume":"12","author":"RM Burke","year":"2019","unstructured":"Burke, R. M., Lighthouse, J. K., Mickelsen, D. M. & Small, E. M. Sacubitril\/Valsartan decreases cardiac fibrosis in left ventricle pressure overload by restoring pkg signaling in cardiac fibroblasts. Circ. Heart Fail. 12, e005565 (2019).","journal-title":"Circ. Heart Fail."},{"key":"62203_CR10","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.jcmg.2016.10.007","volume":"10","author":"CWL Chin","year":"2017","unstructured":"Chin, C. W. L. et al. Myocardial fibrosis and cardiac decompensation in aortic stenosis. JACC Cardiovasc. Imaging 10, 1320\u20131333 (2017).","journal-title":"JACC Cardiovasc. Imaging"},{"key":"62203_CR11","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1161\/01.CIR.102.12.1388","volume":"102","author":"CG Brilla","year":"2000","unstructured":"Brilla, C. G., Funck, R. C. & Rupp, H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 102, 1388\u20131393 (2000).","journal-title":"Circulation"},{"key":"62203_CR12","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1161\/01.CIR.0000017264.66561.3D","volume":"105","author":"J D\u00edez","year":"2002","unstructured":"D\u00edez, J. et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 105, 2512\u20132517 (2002).","journal-title":"Circulation"},{"key":"62203_CR13","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1016\/j.jacc.2003.12.052","volume":"43","author":"B L\u00f3pez","year":"2004","unstructured":"L\u00f3pez, B. et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J. Am. Coll. Cardiol. 43, 2028\u20132035 (2004).","journal-title":"J. Am. Coll. Cardiol."},{"key":"62203_CR14","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1161\/CIRCULATIONAHA.105.571653","volume":"112","author":"H Izawa","year":"2005","unstructured":"Izawa, H. et al. Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation 112, 2940\u20132945 (2005).","journal-title":"Circulation"},{"key":"62203_CR15","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1016\/j.jacc.2009.08.021","volume":"54","author":"GJ Mak","year":"2009","unstructured":"Mak, G. J. et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J. Am. Coll. Cardiol. 54, 1674\u20131682 (2009).","journal-title":"J. Am. Coll. Cardiol."},{"key":"62203_CR16","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.jcmg.2011.08.014","volume":"4","author":"W Kosmala","year":"2011","unstructured":"Kosmala, W. et al. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome. JACC Cardiovasc. Imaging 4, 1239\u20131249 (2011).","journal-title":"JACC Cardiovasc. Imaging"},{"key":"62203_CR17","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1136\/heartjnl-2012-303329","volume":"99","author":"W Kosmala","year":"2013","unstructured":"Kosmala, W., Przewlocka-Kosmala, M., Szczepanik-Osadnik, H., Mysiak, A. & Marwick, T. H. Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade. Heart 99, 320\u2013326 (2013).","journal-title":"Heart"},{"key":"62203_CR18","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1093\/eurheartj\/ehv142","volume":"36","author":"C Bavishi","year":"2015","unstructured":"Bavishi, C., Messerli, F. H., Kadosh, B., Ruilope, L. M. & Kario, K. Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials. Eur. Heart J. 36, 1967\u20131973 (2015).","journal-title":"Eur. Heart J."},{"key":"62203_CR19","doi-asserted-by":"crossref","unstructured":"Schmieder, R. E. et al. The effect of sacubitril\/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study. Eur. Heart J. 38, 3308\u20133317 (2017).","DOI":"10.1093\/eurheartj\/ehx525"},{"key":"62203_CR20","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon, S. D. et al. Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction. N. Engl. J. Med. 381, 1609\u20131620 (2019).","journal-title":"N. Engl. J. Med."},{"key":"62203_CR21","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1016\/j.jacc.2019.09.063","volume":"74","author":"AM Shah","year":"2019","unstructured":"Shah, A. M. et al. Echocardiographic features of patients with heart failure and preserved left ventricular ejection fraction. J. Am. Coll. Cardiol. 74, 2858\u20132873 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"62203_CR22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.pcad.2021.03.007","volume":"67","author":"A Palazzuoli","year":"2021","unstructured":"Palazzuoli, A. et al. Current gaps in HFpEF trials: time to reconsider patients\u2019 selection and to target phenotypes. Prog. Cardiovasc. Dis. 67, 89\u201397 (2021).","journal-title":"Prog. Cardiovasc. Dis."},{"key":"62203_CR23","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201910865","volume":"12","author":"M Sweeney","year":"2020","unstructured":"Sweeney, M., Corden, B. & Cook, S. A. Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?. EMBO Mol. Med. 12, e10865 (2020).","journal-title":"EMBO Mol. Med."},{"key":"62203_CR24","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/s41591-021-01452-0","volume":"27","author":"GA Lewis","year":"2021","unstructured":"Lewis, G. A. et al. Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial. Nat. Med. 27, 1477\u20131482 (2021).","journal-title":"Nat. Med."},{"key":"62203_CR25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.117.006840","volume":"10","author":"VJ Goh","year":"2017","unstructured":"Goh, V. J. et al. Novel Index of maladaptive myocardial remodeling in hypertension. Circ. Cardiovasc. Imaging 10, e006840 (2017).","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"62203_CR26","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.jacc.2014.01.068","volume":"63","author":"EB Schelbert","year":"2014","unstructured":"Schelbert, E. B., Fonarow, G. C., Bonow, R. O., Butler, J. & Gheorghiade, M. Therapeutic targets in heart failure: refocusing on the myocardial interstitium. J. Am. Coll. Cardiol. 63, 2188\u20132198 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"62203_CR27","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1016\/j.jcmg.2019.04.025","volume":"12","author":"EB Schelbert","year":"2019","unstructured":"Schelbert, E. B., Butler, J. & Diez, J. Why clinicians should care about the cardiac interstitium. JACC Cardiovasc. Imaging 12, 2305\u20132318 (2019).","journal-title":"JACC Cardiovasc. Imaging"},{"key":"62203_CR28","doi-asserted-by":"publisher","first-page":"1248468","DOI":"10.3389\/fcvm.2023.1248468","volume":"10","author":"V Lee","year":"2023","unstructured":"Lee, V. et al. Sacubitril\/valsartan versus valsartan in regressing myocardial fibrosis in hypertension: a prospective, randomized, open-label, blinded endpoint clinical trial protocol. Front. Cardiovasc. Med. 10, 1248468 (2023).","journal-title":"Front. Cardiovasc. Med."},{"key":"62203_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12968-016-0236-3","volume":"18","author":"TT Le","year":"2016","unstructured":"Le, T. T. et al. Cardiovascular magnetic resonance reference ranges for the heart and aorta in Chinese at 3T. J. Cardiovasc. Magn. Reson. 18, 21 (2016).","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"62203_CR30","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/jch.12237","volume":"16","author":"MA Weber","year":"2014","unstructured":"Weber, M. A. et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J. Clin. Hypertens. 16, 14\u201326 (2014).","journal-title":"J. Clin. Hypertens."},{"key":"62203_CR31","unstructured":"Ministry of Health, Singapore. MOH clinical practice guidelines on hypertension 1\/2017. Ministry of Health, Singapore; https:\/\/www.moh.gov.sg\/docs\/librariesprovider4\/guidelines\/cpg_hypertension-booklet---nov-2017.pdf (2017)."},{"key":"62203_CR32","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1161\/HYPERTENSIONAHA.122.19225","volume":"79","author":"NR Iyer","year":"2022","unstructured":"Iyer, N. R. et al. Markers of focal and diffuse nonischemic myocardial fibrosis are associated with adverse cardiac remodeling and prognosis in patients with hypertension: the REMODEL study. Hypertens 79, 1804\u20131813 (2022).","journal-title":"Hypertens"},{"key":"62203_CR33","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/ehjci\/jeaa040","volume":"22","author":"TT Le","year":"2021","unstructured":"Le, T. T. et al. The remodelling index risk stratifies patients with hypertensive left ventricular hypertrophy. Eur. Heart J. Cardiovasc. Imaging 22, 670\u2013679 (2021).","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"62203_CR34","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/ejhf.2456","volume":"24","author":"H Holm","year":"2022","unstructured":"Holm, H., Magnusson, M., Juji\u0107, A., Bozec, E. & Girerd, N. How to calculate ventricular\u2013arterial coupling?. Eur. J. Heart Fail. 24, 600\u2013602 (2022).","journal-title":"Eur. J. Heart Fail."},{"key":"62203_CR35","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1093\/eurheartj\/ehac207","volume":"43","author":"P Garg","year":"2022","unstructured":"Garg, P. et al. Cardiac magnetic resonance identifies raised left ventricular filling pressure: prognostic implications. Eur. Heart J. 43, 2511\u20132522 (2022).","journal-title":"Eur. Heart J."},{"key":"62203_CR36","doi-asserted-by":"crossref","unstructured":"Cai, J. et al. Fractal analysis of left ventricular trabeculations is associated with impaired myocardial deformation in healthy Chinese. J. Cardiovasc. Magn. Reson. 19, 102 (2016).","DOI":"10.1186\/s12968-017-0413-z"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62203-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62203-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62203-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T07:41:44Z","timestamp":1757317304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62203-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["62203"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-62203-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"24 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.S.P.L. has received consulting fees from Novartis. J.B. is a consultant to Novartis. The other authors do not have any relevant conflicts of interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6981"}}